≤PE-AT>Professor Stephen Ackland MMBS, FRACP, GAICD

Current major positions: Senior Staff Specialist in Medical Oncology, Calvary Mater Newcastle hospital; Professor, Faculty of Health and Medicine, University of Newcastle; Director, Hunter Cancer Research Alliance; Director, AGITG; Editor-in-Chief, Asia Pacific Journal of Clinical Oncology.

Previous positions include Chair of MOGA, President of COSA, Chair of Board of ANZ Breast Cancer Trials.

Research profile is in GI and breast cancer, in cancer pharmacogenomics and pharmacokinetics. As Director of HCRA with >300 cancer researcher members, makes a substantial contribution via Cancer Institute NSW to statewide strategies for cancer research and its implementation into the healthcare system. Multiple peer review and discipline/community contributions.

Has developed and promoted a facility for Therapeutic Drug Monitoring of mitotane for adrenocortical cancer, with now an average 5--6 samples per week tested. Currently undertaking a study to refine TDM so that therapeutic plasma levels are reached quickly.

Mr Paul Anderson is a Consultant Urologist at the Royal Melbourne Hospital and Epworth Hospital.

He has an active research portfolio involving surgical, medial and biomarker trials particularly in the field of bladder cancer. He is a reviewer for a number of journals, sits on the Melbourne Health Ethics Committee for Research and is an examiner for the Urology Fellowship Examinations.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/ajco.13192](#).

This article is protected by copyright. All rights reserved.

A/Prof. Arun Azad is a medical oncologist and translational researcher with a sub-specialist interest in prostate and urological cancers. He is co-lead of the Movember/Cancer Australia Up-Front PSMA Alliance and serves as Translational Research Subcommittee Chair at ANZUP Cancer Trials Group.

Dr Alison Birtle is a consultant clinical oncologist and Honorary senior lecturer at the Rosemere cancer centre, Lancashire teaching hospitals, Preston, specialising in the treatment of urological cancers. Her MD thesis was in PSA negative prostate cancers at the institute of Urology.

She is advisor to Macmillan on patient information for prostate, bladder and testicular tumours, Trustee and medical advisor to Fight Bladder cancer, and Secretary to the British Uro Oncology Group. She has published widely and lectures nationally and internationally.

Alison has been Clinical research Lead for Lancashire and South Cumbria cancer Research network, and more recently, Associate Clinical Lead for cancer Research and since March 2018, Speciality Group Lead for cancer research for North West Coast CRN>

She is a former member of the prostate CSG and stepped down as chair of the Bladder/renal NIHR Clinical study group in 2018 after two terms. She remains a member of the advanced bladder cancer subgroup.

Dr Birtle has been principal investigator and chief investigator on numerous urological clinical trials and is the Chief Investigator on the POUT trial.

In 2018, she was awarded one of the national 70 stars of the NHS award by NSH England and the NHS Confederations part of the NHS 70 anniversary.

She was also awarded NWCCRN Research Practitioner of the Year in 2018, and more locally runner up in Lancashire doctor of the year.

This article is protected by copyright. All rights reserved.

She is passionate about patient access to clinical trials and believes in the mantra of a trial for every patient.

Nick Brook has been a consultant urological surgeon at the Royal Adelaide Hospital and Clinical Associate Professor in Surgery at the University of Adelaide since 2009. His private practice is located at Calvary North Adelaide Hospital, 89 Strangways Terrace, North Adelaide, with appointments at Calvary North Adelaide Hospital and Burnside War Memorial Hospital.

Nick completed surgical urology training in the UK, before undertaking an advanced laparoscopic and cancer fellowship placement at the Princess Alexandra Hospital in Brisbane from 2008--2009.

Nick holds Fellowships of both UK (FRCS Urol) and Australasian (FRACS Urol) Colleges of Surgeons, a Doctor of Medicine higher degree by research (MD), a MBBS, and extensive basic science research training (BSc and MSc).

He is trained in all aspects of adult urology practice, and has a special interest in urological cancers. He has subspecialist experience in kidney, bladder and testicular cancer, including minimally invasive surgical treatment for kidney cancer, and an interest in modern treatment of prostate cancer with brachytherapy.

Nick also has extensive experience in the management of urological conditions in patients with complex medical problems and kidney failure.

His clinical and basic science research interests encompass novel treatments for advanced prostate cancer, and is the lead urologist on a number of clinical trials based at the Royal Adelaide Hospital. He has published extensively in peer-reviewed journals and has presented at numerous international meetings.

A/Prof Lisa Butler is a Cancer Council Principal Research Fellow at the University of Adelaide and heads the Prostate Cancer Research Group at the South Australian Health and Medical Research Institute. She holds a Ph.D. in cancer biology from the University of Adelaide with postdoctoral training in preclinical drug development at Memorial Sloan-Kettering Cancer Centre in New York, and was most recently an ARC Future Fellow (2014-18).

A/Prof Butler's research focuses on novel combinatorial approaches to target androgen signalling therapeutically in prostate cancer and biomarker discovery. She also has a strong interest in the development and utilisation of novel preclinical models of disease, including mouse models and human tumour explants.

Professor Suzanne Chambers University Technology Sydney (UTS), Sydney, Australia Professor Suzanne Chambers is Dean of the Faculty of Health at the University of Technology Sydney. Prior to joining UTS, she was the Director of the Menzies Health Institute of Queensland at Griffith University.

She is a health psychologist and registered nurse who has worked as a practitioner and researcher in psychological support for people with cancer for over 30 years.

Professor Chambers is an Officer of the Order of Australia for distinguished service to medical research, particularly in the area of psycho-oncology, and to community health through patient care strategies to assist men with prostate cancer.

She has published extensively on the psychological effects of cancer with over 200 peer reviewed publications and books and has been a chief investigator on successful research grants valued at over \$30 million from the NHMRC, ARC, Prostate Cancer Foundation of Australia, Cancer Australia, Beyond Blue and Cancer Council Queensland. She leads the current NHMRC Centre for Research Excellence in Prostate Cancer Survivorship.

Professor Chambers holds adjunct professorships at Griffith University, Edith Cowan University, the University of Queensland and the University of Southern Queensland.

A/Prof Niall Corcoran is a urological surgeon at the Royal Melbourne and Frankston Hospitals, and a principal research fellow in the Department of Surgery, University of Melbourne. He is also the Research and Education Lead for GU oncology for the Victorian Comprehensive Cancer Centre, with a brief to promote collaboration both within the VCCC alliance partners as well with other Victorian and interstate centres. He leads one of the recently awarded Federal Government/Movember Prostate Cancer Research Alliance Awards, which he will speak about this morning.

Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University and Eastern Health, in Melbourne, Australia. He is an NHMRC Practitioner Fellow. He holds honorary appointments with the Olivia Newton-John Cancer Research Institute (formerly Ludwig Institute for Cancer Research) and Austin Health, is an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and in melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers. Prof Davis is a member of the Standing Subcommittee on Research for the Cancer Council Victoria.

He is the founder of the Urologic Oncology Group of the Clinical Oncology Society of Australia (COSA), a member of COSA Council and previously a COSA Board director, and is founder of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd (ANZUP). He is chair of the ANZUP Board and of its Scientific Advisory Committee.

A/Prof. Haryana Dhillon (BSc MA PhD) is a Senior Research Fellow, who co-leads the Survivorship Research Group and is a Director of the Centre for Medical Psychology and Evidence-based Decision-making, School of Psychology, USYD. Her research interests are broad encompassing cancer survivorship, health literacy, and interventions for survivorship, symptom management, and psycho-oncology. Haryana is active in several of the Australasian Cancer Cooperative Trials Groups, and is committed to the collaborative research process. She tweets for herself and a number of organisations. She is known for live tweeting conferences and events.

(NO PHOTO RECEIVED AS YET)

Dr Alasdair Foster is a writer, curator and researcher who works worldwide, especially in Asia and Latin America. He is currently Professor of Culture in Community Wellbeing in the School of Public Health at the University of Queensland exploring practical ways to improve human wellbeing and recovery at the nexus of the arts, humanities and medical/health sciences. He is also Adjunct Professor in the School of Art of RMIT University, Melbourne, and a member of the university's Contemporary Art and Social Transformation research group. In 2018, he was Leverhulme Visiting Professor at the University of Dundee, Scotland, where he worked with staff on the development of innovative pedagogic approaches to community engagement that promote the flourishing of both students and the wider community.

Alasdair has twenty years' experience heading national arts institutions in Europe and Australia and over 35 years of working in the public cultural sector. A polymath, he has worked as an artist, curator, writer, editor, researcher, policy advisor and photographer, integrating each experience into an expansive worldview.

A/Prof Craig Gedye

Why do treatments work for some patients but not others? Why does a cancer recur in some people? Why do some cancers behave more aggressively than others? Unlocking answers to these questions will help us improve the outcomes and experience of people living with cancer.

My research focus is on “cancer heterogeneity”; this challenging problem spans projects across the research spectrum, from patient experience, through clinical trials, translational biomarkers and questions in basic science.

I’m a physician/scientist, dual trained as a medical oncologist and basic science researcher. I work for patients with melanoma, brain, kidney, prostate, testis, and bladder cancer at the Calvary Mater Newcastle, and I’m the Clinical Research Director at the NSW Statewide Biobank. I chair the Renal Cancer Subcommittee for the ANZUP Cancer Trials Group, and undertake translational cancer research at the Hunter Medical Research Institute, University of Newcastle.

Peter Grimison is a Staff Specialist in Medical Oncology at the Chris O’Brien Lifehouse in Sydney, Visiting Medical Officer at Royal Prince Alfred Hospital, and Clinical Associate Professor at the University of Sydney. His clinical work focuses on testicular cancer, sarcoma, and upper gastrointestinal cancers. He is actively involved in research about testicular cancer: study chair for the ANZUP phase 3 accelerated BEP study, ANZUP lead investigator for the Alliance TIGER study of high-dose chemotherapy for relapsed germ cell tumours. He serves as a member of the Australian Government Pharmaceutical Benefits Advisory Committee, and a number of other Federal and NSW Government committees. He is also committed to teaching as Director of Physician Training in

This article is protected by copyright. All rights reserved.

Medical Oncology at the Chris O'Brien Lifehouse, and also actively teaches in Basic Physician Training and the University of Sydney Medical Program

Professor Howard Gurney is a medical oncologist and Head of the Clinical Trials Unit in Macquarie University Hospital and is also a staff specialist at Westmead Hospital. His subspecialty interests are in prostate cancer and other genitourinary cancers (bladder, testis and kidney cancer). He is involved with the introduction of new drug therapies in cancer patients, particularly for prostate, kidney cancer and bladder cancer.

Dr Fritha Hanning is a graduate of the University of Auckland School of Medicine, having previously studied at Otago University. During her advanced training she worked in the United Kingdom at the Royal London and St Bartholomew's hospitals, the Royal Free Hospital London, and at Cancer Research UK in Oxford. She works exclusively in Genitourinary oncology outside of her leadership positions.

Fritha is the service clinical director for the Medical Oncology Unit at Auckland City Hospital. She contributes to the ANZUP scientific committee and the Genitourinary Oncology Special Interest Group for New Zealand of which she was a founding member. She is a Chartered Member of the New Zealand Institute of Board of Directors.

In her free time Fritha is a committed crossfitter and has latterly taken up masters Olympic weightlifting.

Cynthia Hawks

(NO BIO RECEIVED AS YET)

Dr Amy Hayden is a Radiation Oncologist at Westmead Cancer Centre, with a large subspecialty practice in prostate and genitourinary cancer. She completed her fellowship training in 2008 and was awarded the college gold medal. Amy went on to undertake a prostate research fellowship at the British Columbia Cancer Centre, Vancouver - focussing on prostate brachytherapy and QOL after prostate cancer treatment. She is a member of the Faculty of Radiation Oncology Genito-Urinary Advisory Group executive, and first author of the FROGG Australian guidelines for prostate radiotherapy.

Professor Dickon Hayne is a urologic surgeon who leads urological research and undergraduate education in urology, at the University of Western Australia. He is Head of Urology for the South Metropolitan Health Service in WA and is lead clinician for the Urological Tumour Collaborative of the WA Cancer and Palliative care Network (WACPCN). Dickon Chairs the Bladder Urothelial and Penile (BUP) Cancer Sub-committee of ANZUP, is an SAC member, leads the BCGMM trial and is

This article is protected by copyright. All rights reserved.

widely engaged in ANZUPs other sub-committees, trials and activities. His major clinical and research interests are urological cancer, in particular bladder cancer.

Dr Christopher Hocking obtained his medical degree from the University of Adelaide. He completed his Medical Oncology training in 2013 with a clinical fellowship in Colorectal Cancer. His primary interest is in genitourinary and gastrointestinal malignancies. He is based at the Lyell McEwin Hospital, Adelaide, where he is the Director of the Medical Oncology Department and Medical Oncology Clinical Trials Unit.

Professor Michael Hofman is a nuclear medicine physician at the Peter MacCallum Cancer Centre in Melbourne, Australia's only public hospital dedicated to cancer treatment, research and education. He has a co-appointment at the University of Melbourne and previously completed a fellowship at Guy's & St Thomas' hospital in London.

He has particular interest in novel radiotracers for imaging and therapy of prostate cancer. He is the principal investigator of the Movember/PCFA "proPSMA Study", a 10-site randomised trial of PSMA PET for staging high risk prostate cancer.

He led the first prospective data on Lu-177-PSMA, is chair of the ANZUP/PCFA "TheraP Study", a multi-centre randomised trial of PSMA theranostics, and co-leads a Movember/Cancer Australia Prostate Cancer Research Alliance evaluating up-front use of PSMA theranostics.

He has authored or co-authored over 120 peer-reviewed articles and several book chapters. He serves as a scientific member for the Australasian Radiopharmaceutical Trials Network (ARTnet) and an associate editor for several journals including the Journal of Nuclear Medicine.

Prof Lisa Horvath is the Director of the Department of Medical Oncology and Director of Research at Chris O'Brien Lifehouse. She completed medical school at the University of Sydney and trained in medical oncology at Royal Prince Alfred Hospital, where she was appointed to the senior staff in 2003. She completed her PhD in translational research at the Garvan Institute of Medical Research in 2004. Lisa's research interest is predominantly in the field of prostate cancer. She is involved with a large number of clinical trials in prostate and colorectal cancers.

Lisa holds academic appointments at both the University of Sydney and the University of New South Wales and is the Head of Prostate Cancer Therapeutics at The Kinghorn Cancer Centre/Garvan Institute of Medical Research. She is the Conjoint Chair of Medical Oncology (Genitourinal Cancers) at Lifehouse. She has published more than 100 original research papers published in peer-reviewed journals in the last 19 years. She has presented extensively at national and international meetings both peer-reviewed and invited presentations.

Dr Edmond Kwan is a Medical Oncologist and translational researcher at Monash Health in Melbourne. His primary research interest is in genitourinary malignancies and circulating biomarker research, stemming from his time as the Early Drug Development Clinical Research Fellow at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital.

He is currently completing his PhD at Monash University, focusing on identifying mechanisms of drug resistance in advanced prostate cancer through the analysis of circulating DNA and RNA in the blood, supported by a postgraduate scholarship from the National Health and Medical Research Council (NHMRC).

This article is protected by copyright. All rights reserved.

Dr Mitchell Lawrence is a Research Fellow in the Department of Anatomy and Developmental Biology and Biomedicine Discovery Institute, Monash University. He graduated with a PhD from Queensland University of Technology in 2009 before joining the Prostate Cancer Research Group at Monash University. His expertise includes the use of patient-derived xenografts of prostate cancer as preclinical models for studying tumour biology and testing novel therapies. His research also focusses on the tumour microenvironment of prostate cancer, particularly the features of cancer-associated fibroblasts. For these multidisciplinary studies, Dr Lawrence works with a diverse team of collaborators, including urologists, oncologists, pathologists, bioinformaticians and patient advocates.

Dr Lawrence is the recipient of funding from the National Health and Medical Research Council (Early Career Fellowship, project grants), the Victorian Government through the Victorian Cancer Agency (Early Career Seed Grant, Mid-Career Fellowship), the Prostate Cancer Foundation of Australia (Movember Young Investigator Grant) and several philanthropic organisations.

A/Prof Mark Lazenby

As an Associate Professor of Nursing, Mark Lazenby explores how nursing practice addresses some of life's biggest questions. He does this through the unique lens of being an advanced practice cancer nurse (MSN, Yale) and a philosopher of religion (PhD, Boston University). Mark studies the psychosocial and palliative care needs of patients who are in treatment for advanced cancer. His currently funded research is on the supportive care of Muslims who are in treatment for life-limiting cancer in the United States. He began this work while on a Fulbright Research Scholar in the King Hussein Cancer Center but became interested in the needs of Muslims who are in treatment in a

This article is protected by copyright. All rights reserved.

non-Muslim majority setting. He also works with colleagues in Botswana to increase access to palliative care for cancer patients, both in the hospital and in the

home.

Dr Kate Mahon

**Chris O'Brien Lifehouse and The Garvan Institute for Medical Research
Sydney, Australia**

Kate is a Medical Oncologist at Chris O'Brien Lifehouse and Royal Prince Alfred Hospital and a post-doctoral research fellow at the Garvan Institute for Medical Research. Her current research is primarily focused on implementing effective biomarkers into clinical practice in advanced prostate cancer.

Professor Declan G. Murphy

Declan Murphy is Consultant Urologist and Director of GU Oncology at Peter MacCallum Cancer Centre, Melbourne, and Professorial Fellow at the University of Melbourne. He completed his urology training at Guy's and St Thomas' NHS Foundation Trust in London, and did Fellowship training in GU Oncology and Robotic Surgery in Melbourne. He was Consultant Urologist at Guy's prior to returning to Melbourne to lead the GU Oncology program at Peter Mac in 2010.

Declan is an internationally-recognised key opinion leader in GU Oncology, prostate cancer in particular, and has published hundreds of peer-reviewed papers. He has a h-index of 35, and has been Chief Investigator on competitive grants worth many millions of dollars. He holds senior editorial positions at the BJUI, European Urology, Nature Reviews Urology, and Prostate Cancer & Prostatic Diseases, and is on the board of reviewers for many other journals. Declan has led the social media strategy at BJUI and is very active on Twitter with over 7000 followers.

This article is protected by copyright. All rights reserved.

J. Kellogg Parsons, MD, MHS, FACS is Professor of Urology, Endowed Chair in Clinical Research, and Director of Genitourinary Clinical and Translational Research in the Department of Urology at the Moores UC San Diego Comprehensive Cancer Center. His research focuses on prostate cancer, benign prostatic hyperplasia (BPH), and patient safety. He is a principle investigator for multi-center clinical trials funded by the National Cancer Institute (NCI) and the Department of Defense. He is an author on over 130 peer-reviewed publications, including papers in *The New England Journal of Medicine*, *The Journal of the American Medical Association*, and *European Urology*. He is an Associate Editor for *Prostate Cancer Prostatic Diseases* and a consulting editor for *European Urology*. Dr. Parsons serves on several high profile, national clinical guidelines and clinical research panels in the USA. He is Vice-chair of the National Comprehensive Cancer Network (NCCN) Panel on Prostate Cancer Early Detection; Chair of the GU Surgery Committee of the National Cancer Institute (NCI) Alliance for Clinical Trials in Oncology; a member of the national Practice Guidelines Panel for the American Society of Clinical Oncology (ASCO); a member of the American Urological Association (AUA) Clinical Guidelines Panel for benign prostatic hyperplasia; and a member of the prostate cancer task force for the National Cancer Institute.

Dr. Parsons' practice focuses on prostate cancer, bladder cancer, and complex BPH. He has extensive expertise in robotic prostatectomy, prostate magnetic resonance imaging (MRI), MRI-guided prostate biopsy, and prostate cryosurgery, including MRI-guided focal therapy. He has been peer-elected to the America's Best Doctors® and the San Diego Medical Society Top Doctors lists for several years. Dr. Parsons is also the award-winning author of the acclaimed novels *DOING HARM* (St. Martin's Press, 2014) and *UNDER THE KNIFE* (St. Martin's Press, 2017)
<http://kellyparsonsbooks.com>

This article is protected by copyright. All rights reserved.

Dr Catherine Paterson (PhD, all with Distinctions: BA, MSc, RAN, PgCert LTA, FHEA, Non-Medical Prescriber) is a clinical academic nurse with expertise in prostate cancer. She has published widely and has been successful in being awarded more than £2 million pounds of research funding. She has advanced clinical practice in prostate biopsy, fiducial gold seed insertion (for IMRT), and has set up and led a number of nurse-led prostate cancer clinics to address areas of unmet supportive care needs. Catherine is part of a large international research team to carry out systematic review work under the auspices of the European Association of Urology Guidelines Office Board and the European Association of Urology Prostate Cancer Guidelines Panel”.

Elizabeth R. Plimack is an Associate Professor of Medical Oncology, Chief of the Division of Genitourinary Medical Oncology and Director of Genitourinary Clinical Research at Fox Chase Cancer Center (FCCC). She is an expert on the treatment of genitourinary malignancies with a focus on bladder and kidney cancers. Her research effort is directed towards the discovery of novel therapeutic approaches and predictive biomarkers for patients with bladder and kidney cancers.

Dr. Plimack has extensive clinical trial experience with immunotherapies and novel combination therapies. She serves on the National Comprehensive Cancer Network guidelines panels for Bladder, Kidney and Prostate cancer, the Bladder Cancer Advocacy Network Management and Think Tank Steering Committees, and on the American Joint Committee on Cancer (AJCC) Urinary Tract Expert Panel. Dr. Plimack received her undergraduate degree from Yale University and completed her M.D. degree and residency in Internal Medicine at the New York University School of Medicine. She went on to a Medical Oncology Fellowship at the MD Anderson Cancer Center, and received a Master’s in Patient Based Biologic Research from the University of Texas Graduate School of Biomedical Science.

This article is protected by copyright. All rights reserved.

Orlando Rincones is a psycho-oncology researcher at the Ingham Institute of Applied Medical Research in Sydney. He has a background in psychology and is currently doing a Master's degree in health research. His main interests are decision-making, improving cancer care and quality of life of cancer patients. He has worked on quantitative and qualitative studies focused on men with prostate cancer and testicular cancer. He played a key role in the recently published 'Prostatectomy versus Radiotherapy for Early-stage PRostate Cancer: PREPaRE' study, which evaluated the information and decision-making needs of men with localized prostate cancer choosing between robotic prostatectomy and radiotherapy. He is currently coordinating the Below the Belt funded PRO-Quest study, which is developing and piloting a Question Prompt List to aid informed treatment decision making in men diagnosed with Localised Prostate Cancer.

Kath Schubach

Kath is a GU Nurse Practitioner working in private practice in metropolitan Melbourne and rural Victoria. She has had 20 years' previous experience at Peter MacCallum Cancer Centre. Drawing on qualifications and experience across two core areas cancer and urology, her practice specialises in individual care that promotes optimal patient outcomes. Kath has expertise in managing sexual dysfunction for oncology/urology patients. She has a master in Nursing Science and postgraduate qualifications in oncology, urology and continence, nursing. She is currently Vice President of Australian & New Zealand Urology Nurses Board, member of Victorian Urological Nurses Society and is a member of the ANZUP Scientific Advisory Committee.

(NO PHOTO RECEIVED AS YET)

Shomik Sengupta is a consultant urologist at Eastern Health, Melbourne and Professor of Surgery at the Eastern Health Clinical School of Monash University. Shomik has a practice with a uro-oncology subspecialty interest – including open, laparoscopic and robotic cancer surgery. He completed his urological training through the Victorian Section of the Urological Society of Australia & New Zealand (USANZ) and subsequently completed a Uro-Oncology fellowship at the prestigious Mayo Clinic, USA. He has also completed a Masters in Surgery (2002) and a Doctorate in Medicine (2014) through the University of Melbourne

Shomik is a strong contributor to USANZ, having been the Chair of the Victorian training subcommittee from 2014 to 2016, and currently as the leader of the GU Oncology advisory group. Shomik also has a strong interest in urologic research, including involvement in clinical trials through the Australian and New Zealand Urogenital & Prostate (ANZUP) cancer trials group, where he is a

This article is protected by copyright. All rights reserved.

member of the Board and the Scientific Advisory Committee. Shomik has more than 100 original publications to date and has been an invited speaker at a number of scientific meetings. Shomik was convenor of the ANZUP Annual Scientific Meeting in 2013 and the scientific program director for the USANZ Annual Scientific Meeting in 2017.

Dr Camille Short is a behavioural scientist and Senior Research Fellow jointly appointed between the Melbourne School of Psychological Sciences and Melbourne School of Health Sciences in 2019 to drive interdisciplinary research in behaviour change, digital health and cancer control. She holds a BPysc with hons (2007) and PhD in Behavioural Medicine (2013) from the University of Newcastle, and has completed advanced post-doctoral training at the University of Adelaide, CQUniversity and Maastricht University in the Netherlands. Her research aims to improve public health by increasing access to high quality multi-disciplinary behaviour change and mental health support through innovative technologies that bridge the gap between what is available in clinic and what is available at home. She has attracted over 1 million AUD in external research funding, including a prestigious National Health and Medical Research Council Fellowship awarded by the Australian

Government.

Dr Christopher Steer

Dr Steer is a medical oncologist working at Border Medical Oncology in the recently completed Albury Wodonga Regional Cancer Centre. He is a conjoint senior lecturer at the UNSW rural clinical school, Albury campus.

Christopher was the inaugural chair of the geriatric oncology interest group of the Clinical Oncological Society of Australia (COSA). He is actively involved in the International Society of Geriatric Oncology (SIOG) and was chair of the scientific committee of the annual scientific meeting

This article is protected by copyright. All rights reserved.

in Prague in November 2015. He is an editorial board member of the Journal of Geriatric Oncology and the European Journal of Surgical Oncology. Christopher is chair of the geriatric oncology interest group of the Multinational Association for Supportive Care in Cancer (MASCC).

Christopher is the current president of the Private Cancer Physicians of Australia (PCPA) and is a member of the MOGA/PCPA cancer drugs working group. Christopher is a principle investigator at the Border Medical Oncology research unit (BMORU). The BMORU has been recognized for innovation in clinical research particularly in delivering care to a rural/regional population. Twitter @drcbsteer

Dr Mark Stein

Mark graduated medicine from the University of Sydney with first class honours, did physician training in endocrinology at The Royal Melbourne Hospital, completed his PhD at Melbourne University followed by a post doc at Tel Aviv University. His public appointments include to The Royal Melbourne Hospital and he has an honorary appointment at The Walter and Eliza Hall Institute. He is a clinician scientist with a background in both clinical and laboratory research across a range of disciplines who continues busy public and private adult endocrine clinical practice.

Adam Stoneley is the Research Operations Manager for the Icon Group, and is a firm advocate of the Group's simple vision to deliver the best care possible to as many people as possible, as close to home as possible. Icon's research activities are coordinated centrally from the Brisbane headquarters with clinical trials underway at 9 satellite outpatient clinics across Australia. With support from the Icon Group and embracing innovations such as tele-trials and satellite site supervision plans, Adam is keen to have most of Icon's 30 clinics across Australia providing clinical research opportunities to the wider community and servicing patient populations with unmet needs.

This article is protected by copyright. All rights reserved.

Sonia Strachan is a Prostate Cancer Support Nurse, her role provides an essential local resource for men and their families who are undergoing treatment for prostate cancer and also focuses on education and awareness of early detection and treatment.

Sonia has a Bachelor of Nursing, Graduate Diploma of Palliative Care & has completed the La Trobe University Prostate Cancer Nurse Course.

Ben Tran is a Medical Oncologist at Peter MacCallum Cancer Centre and Clinician Scientist at the Walter and Eliza Hall Institute. Clinically, his focus lies entirely within the Genitourinary (GU) Tumour stream, in particular, testicular and urothelial cancers. While also focused on GU, his research interests uniquely occupy the two ends of the spectrum in Early Drug Development, and Real World Data (RWD). Ben is actively involved within ANZUP and chairs the Germ Cell Tumour Subcommittee.

Professor Jane Turner

I have worked for over 20 years in the field of Psycho-Oncology as a psychiatrist providing treatment for patients with cancer and their families, and developing a program of research focused on interventions in areas of clinical need, and translational research examining sustainable models of service delivery.

Psycho-Oncology encompasses attention to the psychological, emotional and social needs of people with cancer and their families or carers. It encompasses attention to spiritual and cultural concerns, across all phases of the cancer experience from diagnosis, through treatment, survivorship or advanced diseases. It is a relatively new discipline. The International Psycho-Oncology Society was established in 1984. As such, much of the research in this field has been descriptive and it is only in recent years that robust trials of interventions have become more common, involves attention to the psychological, emotional and social needs of people with cancer and their family or carers.

Dr Ian Vela

Dr Vela is an early career clinician scientist at the APCRC-Q and Consultant Urologist at the Princess Alexandra Hospital with subspecialty training in Urologic Oncology. Dr Vela has a molecular and cellular biology research background and was awarded his PhD from the University of Queensland in 2010, identifying a novel Wnt pathway associated gene (PITX2) in metastatic prostate cancer (publication submitted to Journal of Experimental Metastasis).

During his PhD, Dr Vela secured several grants/scholarships including a Smart State PhD scholarship (2007), Australasian Urologic Foundation scholarship (2006) and a University of Queensland Pathfinder grant (2009). During this time, he collaborated with Team Leaders Prof Clements and Prof Nelson, being co-authors on publications, abstracts and international and national podium and poster presentations. Dr Vela was also an associate supervisor for two PhD students together with Profs Clements and Nelson.

Dr Vela has completed his training in Urology being awarded FRACS Urology in 2012 and was then selected for a two year Society of Urologic Oncology (SUO) Fellowship at the prestigious Memorial Sloan-Kettering Cancer Center in New York, where he, together with Dr Charles Sawyers, Dr Brett Carver, Dr Yu Chen, and Dr Howard Scher (Memorial Sloan-Kettering Cancer Center), and Dr Hans Clevers (Hubrecht Institute in the Netherlands), was instrumental in developing cutting edge "organoid" culture technology.

A/Prof Andrew Weickhardt is a medical oncologist at the Olivia Newton-John Cancer and Wellness Centre in Melbourne. He has an interest in using immunotherapy and personalised treatments for patients with genitourinary cancer. He is actively involved in translational research investigating biomarkers of response and resistance to these treatments, and is involved in several phase 1 trials of new drugs in development, including the ANZUP trial PCR-MIB using pembrolizumab with radiation in early bladder cancer.

Author Manuscript

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Reynolds, B;Nzenza, T;Ngweso, S;Browne, C;MacCraith, E;Manning, T;Sathianathan, N;Mulwijk, T;Pinto, K;Meraney, A;Keane, K;Cecchi, S;Nolazco, JI;Kasivisvanathan, V;Hayne, D;Bolton, D;Lawrentschuk, N

Title:

National Speakers

Date:

2019-07-01

Citation:

Reynolds, B., Nzenza, T., Ngweso, S., Browne, C., MacCraith, E., Manning, T., Sathianathan, N., Mulwijk, T., Pinto, K., Meraney, A., Keane, K., Cecchi, S., Nolzco, J. I., Kasivisvanathan, V., Hayne, D., Bolton, D. & Lawrentschuk, N. (2019). National Speakers. [Abstract]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15 (S4), pp.29-29. <https://doi.org/10.1111/ajco.13192>.

Persistent Link:

<http://hdl.handle.net/11343/286101>